Skip to main content
main-content

04-06-2021 | EULAR 2021 | Conference coverage | Video

RESOLVE-1 fails to meet primary endpoint for lenabasum in patients with dcSSc

Robert Spiera discusses the phase 3 RESOLVE-1 findings for lenabasum in patients with diffuse cutaneous systemic sclerosis, highlighting the possible effects of background immunosuppressive therapy on outcome (7:11).

Read transcript

EULAR 2021 Virtual Congress coverage

Access news and expert commentary from the EULAR 2021 Virtual Congress.

Image Credits